Targeting skeletal and cardiac muscle is a cornerstone of gene therapy for muscular dystrophies (like DMD) and metabolic disorders. Because muscle is the largest organ system by mass, the primary challenge is achieving systemic distribution while minimizing the “liver sink” effect.

Quick Legend: Administration Routes

• IV (Intravenous): Systemic delivery. Essential for whole-body muscle targeting but requires high doses.
• IM (Intramuscular): Direct injection into a specific muscle (e.g., the bicep). Highly efficient for local expression but doesn’t reach other muscles.
• Isolated Limb Perfusion (ILP): A surgical method to circulate the vector through a specific limb’s vasculature, increasing local uptake while reducing systemic exposure.

---

1. Natural AAV Serotypes

Serotype	Primary Target Cells	Preferred Route	Key Characteristics & Notes
AAV1	Skeletal Muscle Fibers	IM	The Local Champion. • Historically the first choice for direct muscle injection. • Excellent for local secretion of proteins into the blood (e.g., Alpha-1 antitrypsin).
AAV6	Skeletal Muscle, Cardiomyocytes	IV / IM	High Potency. • Closely related to AAV1 but significantly better at crossing the vascular barrier to reach muscles from the bloodstream.
AAV8	Skeletal & Cardiac Muscle	IV	Global Distribution. • Very efficient at systemic muscle transduction, but its extreme affinity for the liver often limits the “net” dose that reaches the muscle.
AAV9	Skeletal Muscle, Heart, CNS	IV	The Systemic Standard. • Widely used for systemic muscle diseases. It has a high capacity to escape the vasculature and penetrate muscle tissue.
AAV7	Skeletal Muscle	IV / IM	Similar performance to AAV1/AAV6 in muscle; often used in preclinical NHP (Non-Human Primate) studies but less common in human trials.

---

2. Engineered & Synthetic Capsids

These are designed to increase “Musculotropism” (muscle-seeking) while “Detargeting” (avoiding) the liver.

Variant	Primary Target Cells	Preferred Route	Key Characteristics & Notes
MyoAAV	Skeletal Muscle (All Types)	IV	The New Benchmark. • Engineered with a unique peptide (RGD-motif) that binds to integrins on muscle cells. • 10–50x more potent than AAV9 in muscles while significantly avoiding the liver.
AAV-B1	Skeletal Muscle, Heart, Brain	IV	A bioengineered variant that shows broad muscle transduction and reduced liver sequestration compared to wild-type AAV9.
AAV-SLB	Skeletal Muscle	IV	“Skeletal-Muscle-Bypass.” • Specifically engineered to reduce liver uptake. It shows high specificity for skeletal muscle over other organs.
AAV-myo	Muscle Fibers	IV	A variant developed via directed evolution to specifically improve transduction of dystrophic muscle tissue (which is harder to infect than healthy muscle).

---

3. Tropism by Application

If you are designing a muscle-directed study, start here:

• Duchenne Muscular Dystrophy (DMD): MyoAAV or AAV9 (systemic reach is mandatory to hit the diaphragm and heart).
• Local Protein Factory: AAV1 (via IM injection).
• Diaphragm/Respiratory Muscles: AAV6 or AAV9 (via IV).
• Avoiding Liver Toxicity: MyoAAV or AAV-SLB.

Critical Factor: The Dystrophic Barrier

In diseases like DMD, muscle tissue is not “normal”—it is characterized by inflammation, fibrosis (scarring), and fatty replacement.

1. The Barrier: Fibrosis can physically block AAV particles from reaching the muscle fiber membrane (sarcolemma).
2. The Solution:
   • Higher Titers: Often required to push through the fibrotic tissue.
   • Promoter Choice: Using muscle-specific promoters like MHCK7 or Desmin is crucial. This ensures that even if the AAV enters a liver or immune cell, the therapeutic gene (like Micro-dystrophin) only turns on inside the muscle fibers.